Skip to main content

Table 1 Clinical and histopathological characteristics of cases included in the study

From: TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancer

 

All cases (n = 212)

Microarray (n = 80)

Characteristics

Number

Percent

Number

Percent

Age (year)

    

   <45

24

11.3

6

7.5

   45–55

37

17.5

12

15.0

   55–65

38

17.9

20

25.0

   65–75

50

23.6

21

26.3

   ≥75

63

29.7

21

26.3

Gender

    

   Female

211

99.5

79

98.8

   Male

1

0.5

1

1.2

Type

    

   Ductal

132

64.4

51

63.8

   Lobular

53

25.8

22

27.5

   Mucinous

8

3.9

3

3.8

   Medullary

4

2.0

0

0

   DCIS with microinvasion

1

0.5

1

1.3

   Tubulolobular

2

1.0

2

2.5

   Other

5

2.4

1a

1.3

   Unknown

7

 

0

 

Tumor size

    

   pT1 (≤2 cm)

71

34.6

20

26.0

   pT2 (>2 ≤5 cm)

112

54.6

44

57.1

   pT3 (>5 cm)

15

7.3

8

10.4

   pT4 (infiltrating growth)

7

3.4

5

6.5

   Unknown

7

 

3

 

Node status

    

   pN0 (negative)

95

44.8

33

41.3

   pN1 (1–3 positive)

48

22.6

23

28.8

   pN2–N3 (≥4 positive)

33

15.6

12

15.0

   pNX (Nodes not removed)

36

17.0

12

15.0

Grade

    

   1

19

9.0

6

7.5

   2

141

66.5

53

66.3

   3

48

22.6

21

26.3

   Unknown

4

 

0

 

Estrogen receptor

    

   Positive

109

57.7

45

62.5

   Negative

80

42.3

27

37.5

   Unknown

23

 

8

 

Progesteron receptor

    

   Positive

130

62.8

51

67.1

   Negative

77

37.2

25

32.9

   Unknown

5

 

4

 

TP53 mutation

    

   Mutation

48

23.6

20

25.0

   Wild type

155

76.4

60

75.0

   Unknown

9

 

0

 

Gene expression group

    

   Luminal A

  

23

28.8

   Highly proliferating luminal

  

15

18.8

   Normal-like

  

20

25.0

   Basal-like

  

12

15.0

   ERBB2+

  

10

12.5

Adjuvant therapy

    

   Radiation therapy

    

Yes

60

31.1

25

32.9

No

133

68.9

51

67.1

Unknown

19

 

4

 

   Chemotherapyb

    

Yes

27

12.9

11

14.1

No

182

87.1

67

85.9

Unknown

3

 

2

 

   Hormonal treatmentc

    

Yes

53

25.1

25

31.6

No

158

74.9

54

68.4

Unknown

1

   

Recurrence (distant metastisis)

    

   Positive

72

34.1

34

42.5

   Negative

139

65.9

46

57.5

   Unknown

1

 

0

 

Status

    

   Alive

75

37.5

25

32.5

   Dead of disease

63

31.5

30

39.0

   Dead of other cause

60

30.0

20

26.0

   Emmigrated

2

1.0

2

2.6

   Unknown

12

 

3

 
  1. aRare type with a metaplastic core and spindle cell component. bCMF × 9 (cyclophosphamide, methotrexate, 5-fluorouracil). cTamoxifen; 2 years. DCIS, ductal carcinoma in situ.